MGTA-117 for Acute Myeloid Leukemia

"Eight different medical institutions are participating in this trial. Among these locations, some of the most noteworthy sites include MD Anderson Cancer Center (Houston), Sarah Cannon Research Institute at HealthONE (Denver), and University of Minnesota (Minneapolis)."

"The requirements to join this trial demand applicants between the ages of 18 and 75. If you're younger than that, there are 464 studies available for minors while 1345 trials accept seniors over 65 years old."

"This clinical trial is recruiting 55 people aged 18 to 75 who are diagnosed with myelodysplasia. Additionally, those interested must have experienced primary AML induction failure or R/R AML; a WHO-defined diagnosis of MDS-EB and failed/refractory HMA; MRD in morphologic CR, CD117+ based on IHC or flow cytometry; an identified HSC donor (related donor or unrelated donor), haplo-identical transplant donor, or umbilical blood donor.; ECOG performance status ≤2.; adequate baseline hepatic function including ALT, AST, ALP ≤2 x"

"Affirmative. According to the details published on clinicaltrials.gov, this trial commenced recruiting participants on 14th February 2022 and is currently still active with a most recent update dated 23rd November 2022. The research requires 55 individuals across 8 medical centres."

"Magenta Therapeutics, Inc. requires 55 eligible patients to participate in this trial from several sites across the United States, including MD Anderson Cancer Center located in Houston and Sarah Cannon Research Institute at HealthONE situated in Denver."

"Due to the fact that MGTA-117 is at a Phase 1 trial stage, our team at Power rates its safety as a score of 1. This indicates that there is only sparse evidence available regarding both efficacy and safety."